Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

NCT05266612 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: VG2025
DRUG: Nivolumab Injection [Opdivo]

Sponsor

Virogin Biotech Canada Ltd